Investment Thesis
Forty Seven (FTSV) management must be pleased with the progress they made in December '19.
First of all, early results from clinical trials of the company's flagship drug magrolimab were positive. In a trial evaluating magrolimab in combination with azacitidine for the treatment of myelodysplastic syndrome ("MDS") and acute myeloid leukaemia ("AML"), Complete Response ("CR") rates of 50% and Overall Response Rates ("ORR") of 92% were observed in untreated patients with higher risk MDS.
In Patients with Untreated AML who are ineligible for induction chemotherapy CR and ORR rates were 55%